PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Go back to PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
(NASDAQ: PRTC) Delayed: 17.42 --0 (-0%)
Previous Close $17.42    52 Week High
Open $17.42    52 Week Low
Day High $17.42    P/E N/A 
Day Low $17.42    EPS
Volume 2,348       

(NASDAQ: SPTX) Delayed: 20.57 -0.88 (4.1%)
Previous Close $21.45    52 Week High
Open $21.39    52 Week Low
Day High $21.87    P/E N/A 
Day Low $19.42    EPS
Volume 220,839